A systematic case study on using NMR models for molecular replacement: p53 tetramerization domain revisited

被引:12
|
作者
Chen, YW
Clore, GM
机构
[1] Ctr Prot Engn, Cambridge CB2 2QH, England
[2] Univ Cambridge, Chem Lab, MRC Ctr, Cambridge CB2 2QH, England
[3] NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1107/S0907444900012002
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Molecular replacement using search models derived from nuclear magnetic resonance (NMR) spectroscopy has often proved problematic. It has been known for some time that the overall differences in atomic positions (r.m.s.d.) between the crystalline and the solution states of the same protein are of the order of 1-2 Angstrom and approach the limit of molecular replacement. In most cases, this structural difference is a result of calculating the NMR structure with insufficient data, yielding an NMR structure of limited accuracy. A systematic case study was performed to investigate the use of NMR models for molecular replacement on the p53 tetramerization domain: NMR search models of varying degrees of accuracy were employed to solve phases for the 1.5 Angstrom X-ray diffraction data. An approximate correlation was found between the accuracy of the NMR search model and the clarity and quality of the molecular-replacement solution. It was found that ensemble models perform better than single averaged models and have a larger tolerance in model inaccuracy. Also, distance-derived B factors can improve the performance of single models.
引用
收藏
页码:1535 / 1540
页数:6
相关论文
共 50 条
  • [1] Tracing the Evolution of the p53 Tetramerization Domain
    Joerger, Andreas C.
    Wilcken, Rainer
    Andreeval, Antonina
    STRUCTURE, 2014, 22 (09) : 1301 - 1310
  • [2] The tetramerization domain of p53 is required for efficient BAK oligomerization
    Pietsch, E. Christine
    Leu, J. I-Ju
    Frank, Amanda
    Dumont, Patrick
    George, Donna L.
    Murphy, Maureen E.
    CANCER BIOLOGY & THERAPY, 2007, 6 (10) : 1576 - 1583
  • [3] EVOLUTION OF THE TETRAMERIZATION DOMAIN IN TUMOR SUPPRESSOR PROTEIN P53
    Nakagawa, N.
    Wada, J.
    Kamada, R.
    Nomura, T.
    Imagawa, T.
    Sakaguchi, K.
    JOURNAL OF PEPTIDE SCIENCE, 2016, 22 : S22 - S22
  • [4] Using peptides to study the interaction between the p53 tetramerization domain and HIV-1 Tat
    Gabizon, Ronen
    Mor, Michal
    Rosenberg, Masha M.
    Britan, Lena
    Hayouka, Zvi
    Kotler, Moshe
    Shalev, Deborah E.
    Friedler, Assaf
    BIOPOLYMERS, 2008, 90 (02) : 105 - 116
  • [5] A tetramerization domain in prokaryotic and eukaryotic transcription regulators homologous to p53
    Bernardo, Nerea
    Crespo, Isidro
    Cuppari, Anna
    Meijer, Wilfried J. J.
    Boer, D. Roeland
    ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2023, 79 : 259 - 267
  • [6] A new function for p53 tetramerization domain in cell fate control
    Zhang, Jin
    Lucchesi, Christopher
    Chen, Xinbin
    CELL CYCLE, 2016, 15 (21) : 2854 - 2855
  • [7] A tetraguanidinium ligand binds to the surface of the tetramerization domain of protein P53
    Salvatella, X
    Martinell, M
    Gairí, M
    Mateu, MG
    Feliz, M
    Hamilton, AD
    de Mendoza, J
    Giralt, E
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2004, 43 (02) : 196 - 198
  • [8] COMP 122-An ionic network stabilizes the p53 tetramerization domain
    Lwin, Thu-Zar W.
    Galea, Charles
    Kriwacki, Richard W.
    Bashford, Donald
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 234
  • [9] RhoGAPs Attenuate Cell Proliferation by Direct Interaction with p53 Tetramerization Domain
    Xu, Jie
    Zhou, Xiaolin
    Wang, Jilin
    Li, Zhaoli
    Kong, Xuan
    Qian, Jin
    Hu, Ye
    Fang, Jing-Yuan
    CELL REPORTS, 2013, 3 (05): : 1526 - 1538
  • [10] Methylation of p53 Tetramerization Domain Arginines Residues Destabilize the Tetrameric Structure
    Kameda, Rui
    Anderson, Carl W.
    Sakaguchi, Kazuyasu
    BIOPOLYMERS, 2011, 96 (04) : 524 - 524